Immunovant, Inc. (NASDAQ:IMVT) Stock Has Average Target Price of $44.60

Immunovant logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts have a “Moderate Buy” consensus on Immunovant: nine of 13 rate it a buy, three a hold, and one a sell. The average 12-month price target is $44.60.
  • Immunovant reported a quarterly loss of $0.47 per share, beating the consensus estimate of a $0.74 loss; analysts forecast a loss of $2.49 per share for the current year.
  • Shares opened at $33.17, within a 12-month range of $21.86 to $45.42. Insiders sold shares over the past 90 days, with reported sales made to cover tax withholding on vested equity awards.
  • MarketBeat previews top five stocks to own in December.

Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the thirteen brokerages that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $44.60.

IMVT has been the topic of a number of recent analyst reports. Sanford C. Bernstein raised Immunovant to a "hold" rating in a report on Wednesday, July 29th. Weiss Ratings restated a "sell (d-)" rating on shares of Immunovant in a report on Friday, October 2nd. UBS Group reiterated a "buy" rating on shares of Immunovant in a research note on Wednesday, September 23rd. JPMorgan Chase & Co. raised their price objective on shares of Immunovant from $47.00 to $50.00 and gave the stock an "overweight" rating in a report on Tuesday, August 4th. Finally, HC Wainwright reissued a "buy" rating on shares of Immunovant in a research note on Thursday, September 24th.

Read Our Latest Research Report on IMVT

Immunovant Trading Down 0.1%

NASDAQ:IMVT opened at $33.17 on Thursday. Immunovant has a 12 month low of $21.86 and a 12 month high of $45.42. The company has a market cap of $6.86 billion, a PE ratio of -12.96 and a beta of 0.95. The company has a 50 day simple moving average of $32.28 and a two-hundred day simple moving average of $32.44.

Immunovant (NASDAQ:IMVT - Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.74) by $0.27. During the same quarter in the prior year, the company posted ($0.73) earnings per share. Research analysts forecast that Immunovant will post -2.49 earnings per share for the current year.

Insider Transactions at Immunovant

In other Immunovant news, CFO Tiago Girão sold 6,606 shares of Immunovant stock in a transaction dated Wednesday, October 28th. The shares were sold at an average price of $28.50, for a total value of $188,271.00. Following the completion of the sale, the chief financial officer owned 234,192 shares in the company, valued at $6,674,472. The trade was a 2.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric Venker sold 3,506 shares of the firm's stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $34.11, for a total transaction of $119,589.66. Following the completion of the sale, the chief executive officer owned 257,075 shares in the company, valued at $8,768,828.25. This represents a 1.35% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 27,430 shares of company stock valued at $895,852. Corporate insiders own 1.90% of the company's stock.

Hedge Funds Weigh In On Immunovant

Several large investors have recently made changes to their positions in IMVT. GAMMA Investing LLC lifted its stake in Immunovant by 63.6% in the third quarter. GAMMA Investing LLC now owns 1,224 shares of the company's stock worth $41,000 after acquiring an additional 476 shares during the period. Quantbot Technologies LP purchased a new stake in shares of Immunovant during the 2nd quarter worth approximately $87,000. Sterling Capital Management LLC increased its stake in shares of Immunovant by 856.0% during the third quarter. Sterling Capital Management LLC now owns 2,868 shares of the company's stock worth $97,000 after acquiring an additional 2,568 shares during the period. Nykredit A S purchased a new position in Immunovant during the second quarter worth $174,000. Finally, State of Wyoming purchased a new stake in Immunovant during the 2nd quarter worth $208,000. 47.08% of the stock is currently owned by hedge funds and other institutional investors.

Immunovant Company Profile

(Get Free Report)

Immunovant, Inc. is a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases. Its research focuses on inhibiting the neonatal Fc receptor (FcRn), a pathway involved in maintaining levels of disease-causing antibodies. The company's investigational medicines include batoclimab and IMVT-1402, both designed to reduce circulating antibodies. Immunovant has studied or evaluated these candidates for conditions including myasthenia gravis, Graves' disease and other autoimmune disorders.

See Also

Analyst Recommendations for Immunovant (NASDAQ:IMVT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Immunovant Right Now?

Before you consider Immunovant, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunovant wasn't on the list.

While Immunovant currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines